INS062 + HR20014

INS062 + HR20014 is a combination of two **recombinant polypeptide insulin analogs** developed for subcutaneous administration in healthy subjects, primarily targeting the **treatment of diabetes mellitus**. Both INS062 and HR20014 act as insulin receptor modulators, mimicking the physiological action of endogenous human insulin to regulate blood glucose levels. Clinical studies have focused on their pharmacokinetics, pharmacodynamics, and bioequivalence when compared to established insulin analogs such as NovoRapid or BIAsp 30, establishing their role as investigational biosimilar or novel insulin products. Both molecules are manufactured and tested individually and in combination for safety, efficacy, and bioequivalence in phase 1 clinical trials[2][3][5][7][9][11].

Other names

INS 062INS062INS-062HR 20014HR20014HR-20014